US 10662244
Methods for tumor treatment using CD3XCD20 bispecific antibody
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 10662244 (Methods for tumor treatment using CD3XCD20 bispecific antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K39/39566, A61P